Impact of reverse redistribution of technetium-99m-sestamibi in acute phase on improvement of left ventricular function, brain natriuretic peptide levels, exercise capacity, and prognosis in patients with acute coronary syndrome

Impact of reverse redistribution of technetium-99m-sestamibi in acute phase on improvement of left ventricular function, brain natriuretic peptide levels, exercise capacity, and prognosis in patients with acute coronary syndrome - Impact of reverse redistribution of 99mTc-sestamibi in acute phase on improvement of LV function, BNP levels, exercise capacity, and prognosis in patients with ACS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032436

Enrollment

120

Registered

2018-06-01

Start date

2018-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with ACS who underwent 99mTc-sestamibi myocardial perfusion imaging

Exclusion criteria

Exclusion criteria: Patients who did not undergo ultrasound echocardiography, laboratory test, and cardiopulmonary exercise test

Design outcomes

Primary

Measure	Time frame
Major cardiac events including all cause death, life-threatening arrhythmia, and heart failure requiring hospitalization	—

Secondary

Measure	Time frame
Improvement of LV function, BNP levels, exercise capacity in chronic phase (approximately 3 month after ACS)	—

Countries

Japan

Contacts

Public ContactTakashi Kato

Gifu Prefectural General Medical Center Department of cardiology

katotakashii@estate.ocn.ne.jp058-246-1111

Outcome results